Compare CULP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CULP | BOLD |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.2M | 54.5M |
| IPO Year | 1994 | 2024 |
| Metric | CULP | BOLD |
|---|---|---|
| Price | $3.47 | $2.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.9K | ★ 115.4K |
| Earning Date | 12-09-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.06 | 32.47 |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $203,482,000.00 | N/A |
| Revenue This Year | $3.15 | N/A |
| Revenue Next Year | $1.77 | N/A |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.70 | $0.96 |
| 52 Week High | $4.17 | $3.16 |
| Indicator | CULP | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 50.04 |
| Support Level | $3.46 | $2.43 |
| Resistance Level | $3.48 | $2.65 |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 37.41 | 43.18 |
Culp Inc manufactures, sources, and markets mattress fabrics, sewn covers for mattresses, foundations, and other bedding products, and upholstery fabrics, including cut and sewn kits, for residential, commercial, and hospitality furniture and other applications. It markets fabrics produced at its manufacturing facilities and fabrics sourced through other suppliers to bedding and furniture companies. Its products serve the bedding, residential furnishings, commercial furnishings, and hospitality furnishings markets. Its segments are: Bedding and Upholstery, with Bedding generating the maximum revenue. The Bedding segment supplies the bedding market, comprising mattress sets and bedding accessory products. It generates the maximum revenue from the United States.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.